Streamlining ethical review

Annals of Internal Medicine

Volumn 153, Issue 10, 2010, Pages 655-657

  Millum, Joseph ^a   Menikoff, Jerry ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Office for Human Research Protections   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; HUMAN RIGHTS; INSTITUTIONAL REVIEW; POLICY; PRIORITY JOURNAL; SHORT SURVEY;

EID: 78751682781     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-153-10-201011160-00008     Document Type: Short Survey

References (16)

1. Levine RJ. Institutional review boards: a crisis in confidence [Editorial]. Ann Intern Med. 2001;134:161-3. [PMID: 11177321]
2. Satel S. Clinical trials, wrapped in red tape. New York Times. 8 August 2009:A19.
3. Fost N, Levine RJ. The dysregulation of human subjects research [Editorial]. JAMA. 2007;298:2196-8. [PMID: 18000206] (Pubitemid 350106660)
4. Menikoff J. Where's the law? Uncovering the truth about IRBs and censorship. Northwestern Univ Law Review. 2007;101(2):791-799.
5. Gunsalus C, Bruner E, Burbules N, Dash L, Finkin M, Goldberg J, et al. The Illinois white paper: improving the system for protecting human subjects: Counteracting IRB mission creep. Qualitative Inquiry. 2007;13:617-649.
6. Wagner RM. Ethical review of research involving human subjects: when and why is IRB review necessary? Muscle Nerve. 2003;28:27-39. [PMID: 12811770]
7. Bell J, Whiton J, Connelly S. Evaluation of NIH Implementation of Section 491 of the Public Health Service Act, Mandating a Program of Protection for Research Subjects. Arlington, VA: James Bell Assoc; 1998.
8. Federal policy for the protection of human subjects. Final rule. Fed Regist. 1991;56:28003-18. [PMID: 10112214]
9. U.S. Department of Health and Human Services. Protections of human subjects. 45 CFR Part 46, Subpart A (1991).
10. Office for Human Research Protections. Guidance on Research Involving Coded Private Information or Biological Specimens. Washington, DC: U.S. Department of Health and Human Services; 2008. Accessed at www.hhs.gov/ohrp /humansubjects/guidance/cdebiol.htm on 21 September 2010.
11. U.S. Department of Health and Human Services. Protections of human subjects. 45 CFR §164.514(b) 2002. Accessed at http://edocket.access.gpo. gov/cfr-2002/octqtr/pdf/45cfr164.514.pdf on 21 September 2010.
12. Protection of human subjects: categories of research that may be reviewed by the Institutional Review Board (IRB) through an expedited review procedure - FDA. Notice. Fed Regist. 1998;63:60353-6. [PMID: 10187395]
13. Byrne MM, Speckman J, Getz K, Sugarman J. Variability in the costs of institutional review board oversight. Acad Med. 2006;81:708-12. [PMID: 16868423] (Pubitemid 44167309)
14. Larson E, Bratts T, Zwanziger J, Stone P. A survey of IRB process in 68 U.S. hospitals. J Nurs Scholarsh. 2004;36:260-4. [PMID: 15495496] (Pubitemid 41725181)
15. Infectious Diseases Society of America. Grinding to a halt: the effects of the increasing regulatory burden on research and quality improvement efforts. Clin Infect Dis. 2009;49:328-35. [PMID: 19566438]
16. Office for Human Research Protections. Request for information and comments on IRB accountability. Washington, DC: U.S. Department of Health and Human Services; 2009. Accessed at www.hhs.gov/ohrp/requests/com030509.html on 21 September 2010.